Not a pre-workout. An upstream signal.
A compounded upstream signaling prescription for people treating recovery capacity as part of performance.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
About 10 minutes. No charge unless your clinician approves.
Performance has a hormonal layer too.
The visible part of performance is the work: the session, the load, the pace, the numbers. Underneath it sits the endocrine system that helps govern how the body adapts to repeated demand. CJC-1295 without DAC and ipamorelin are paired around that upstream GH-axis conversation.
This formulation uses CJC-1295 without DAC. Its action is short, measured in minutes rather than days, which keeps growth hormone release pulsatile instead of continuously elevated. The CJC component acts through growth hormone releasing hormone signaling. Ipamorelin stimulates GH release through the growth hormone secretagogue receptor. Two receptor systems, one upstream axis.
That does not make this an acute performance enhancer, and it does not make the combination synthetic HGH. The interest is in short-acting, pulsatile signaling rather than a multi-day background exposure or a direct dose of growth hormone.
This is not a pre-workout, steroid, or synthetic HGH. It is a clinician-reviewed upstream signaling approach for people treating recovery capacity as part of how performance is built.
For athletes who already know effort is not the whole system.
The High-Volume Trainer
Your program is already disciplined and the question is no longer how to work harder. You want the endocrine environment around repeated training evaluated with the same seriousness as the program itself.
The Plateau Analyst
The numbers have flattened even though execution has not. You are interested in a clinician reviewing the GH axis as one possible layer, not in buying a promise that a peptide will break the plateau for you.
The Mechanism-First Athlete
You know CJC-1295 with DAC and without DAC are different products, and you care which one is actually in the vial. You want the short-acting biology explained correctly before you consider anything else.
Compounded CJC-1295 / Ipamorelin is not an FDA-approved drug product. Whether it is appropriate for you is determined by a licensed provider from your full Assessment.
This might not be the right fit if:
- Active or suspected malignancy, or a history of cancer without oncology clearance
- A history of pituitary disease or pituitary surgery, without clearance from the clinician managing it
- Diabetes, prediabetes, or any medication that lowers blood sugar, without clearance from the clinician managing it
- Competing in a tested sport, unless you have confirmed the position with your governing body
- Pregnancy or breastfeeding
- Known hypersensitivity to any component of the preparation
- Under 18
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
CJC-1295 / Ipamorelin (Performance), prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- CJC-1295 confirmed without DAC, with short-acting rather than extended-half-life biology
- Ipamorelin paired as a second upstream GH-secretagogue signal
- Your clinician sets the dose and schedule for the individual prescription
- Training context, medical history, medications, and endocrine factors reviewed before treatment
- Compounded to the individual prescription by a licensed US pharmacy if approved
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Performance.
Wolverine Stack
Two repair pathways. One prescription.
A compounded BPC-157 and TB-500 prescription pairing BPC-157's tissue-repair signaling with thymosin beta-4 biology in cell movement and wound closure.
IGF-1 LR3 (Performance)
The ceiling is recovery, not effort.
A high-scrutiny compounded IGF-1 LR3 prescription for athletes treating recovery capacity as a serious clinical question.
Serious risks
- Both compounds are prohibited at all times by the World Anti-Doping Agency, so if you are a tested athlete, say so at intake
Commonly reported
- Injection site reactions
- Headache
- Diarrhea
- Flushing
The honest disclosure here is the size of the evidence base. Almost all published human data on CJC-1295 describes the long-acting DAC version rather than the short-acting molecule in this preparation. Ipamorelin has one controlled human trial of any size, given intravenously to patients after bowel surgery, where adverse events were common in both the treated and placebo groups; there is no comparable dataset for subcutaneous use in healthy adults. Because both push growth hormone release, your provider screens for active or recent cancer, asks about pituitary history, and reviews blood sugar and any diabetes medication given the ghrelin receptor involvement, and human safety data for this combination remains limited, which is the reason it sits with a clinician rather than in a shopping cart.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
This combination is built around upstream GH-axis signaling, but there are no clinical trials establishing improved muscle gain, strength, endurance, or athletic performance from this compounded preparation in healthy adults.
They act through different upstream receptor systems involved in GH release. The CJC component works through GHRH signaling, while ipamorelin is a growth hormone secretagogue acting through the GHS receptor. The pairing is mechanistically complementary; that does not establish a specific athletic-performance outcome.
Neither this compounded combination nor the finished preparation is FDA-approved. CJC-1295 has no current FDA compounding pathway. Ipamorelin acetate appears on FDA Category 2 for 503B outsourcing facilities, which identifies a published safety concern that the prescribing clinician weighs in deciding whether treatment is appropriate. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.